This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Gastritis and peptic ulcers are among the most common GI problems. Learn how Helicobacter pylori causes them, when you need endoscopy, and how modern eradication therapy works.
# Gastritis and Peptic Ulcer: From Helicobacter to Healing
Gastritis (inflammation of the gastric mucosa) and peptic ulcer disease (a mucosal defect penetrating into the submucosa) are among the most common digestive disorders. Helicobacter pylori infection is found in 50% of the world's population, and 5–10% of people develop peptic ulcer disease during their lifetime. This article provides a detailed breakdown of causes, diagnosis, and modern treatment regimens, including H. pylori eradication.
H. pylori is a gram-negative spiral bacterium, the only microorganism capable of surviving in the acidic gastric environment. It colonizes the mucosal lining, causing chronic inflammation. Mechanism of damage: H. pylori produces urease, which breaks down urea into ammonia, neutralizing acid around the bacterium. It damages the protective mucus barrier, enhances gastrin and hydrochloric acid secretion, and triggers an immune response with neutrophil and lymphocyte recruitment.
Consequences: chronic gastritis → atrophic gastritis → intestinal metaplasia → (in rare cases) gastric cancer. H. pylori causes 80–90% of duodenal ulcers and 60–70% of gastric ulcers. Classified by WHO as a Group 1 carcinogen.
Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, aspirin) suppress COX-1 → reduced prostaglandin synthesis that normally protects the mucosa. The result is erosions and ulcers, especially with prolonged use. Risk is particularly high in the elderly, with concurrent anticoagulants and corticosteroids, and with H. pylori co-infection.
Stress ulcers — in ICU patients (burns, sepsis, traumatic brain injury). Zollinger–Ellison syndrome — a tumor (gastrinoma) producing excess gastrin. Autoimmune gastritis — antibodies against parietal cells → gastric body atrophy → B12 deficiency → pernicious anemia. Alcohol, smoking, spicy food — aggravating factors, but not independent causes of ulcers.
Gastritis: dull epigastric pain or discomfort, nausea, belching, postprandial heaviness, decreased appetite. May be asymptomatic. Gastric ulcer: epigastric pain 15–30 minutes after eating, sometimes weight loss, nausea. Duodenal ulcer: "hunger" pain — 2–3 hours after eating and at night, relieved by food and antacids.
Alarm symptoms (red flags): vomiting blood or "coffee grounds"; black tarry stool (melena); unexplained weight loss; progressive anemia; new-onset symptoms after age 55; dysphagia. These symptoms require urgent endoscopy to rule out malignancy.
Non-invasive: 13C-urea breath test — "gold standard" of non-invasive diagnosis (sensitivity and specificity >95%); stool antigen test (EIA) — comparable accuracy; serology (H. pylori IgG) — shows exposure but cannot distinguish current from past infection.
Invasive (during EGD): rapid urease test (CLO test) — biopsy placed in urea medium; histological examination; bacterial culture with antibiotic sensitivity testing (after first-line eradication failure).
Important: discontinue PPIs 2 weeks and antibiotics 4 weeks before testing. Otherwise, results may be false-negative.
Indications: alarm symptoms; age >55 with new-onset symptoms; treatment failure; follow-up healing of gastric ulcer (duodenal ulcer follow-up usually unnecessary). During EGD, biopsies are taken from the ulcer (to rule out cancer) and from the antrum + body (for CLO test and histology).
If H. pylori is detected, treatment is mandatory for: current or prior ulcer disease, atrophic gastritis, MALT lymphoma, after gastric cancer resection, first-degree relatives of gastric cancer patients, and long-term NSAID/aspirin use.
[Omeprazole](/search?q=omeprazole) 20 mg twice daily (or [pantoprazole](/search?q=pantoprazole) 40 mg twice daily, or [esomeprazole](/search?q=esomeprazole) 20 mg twice daily) + [amoxicillin](/search?q=amoxicillin) 1000 mg twice daily + [clarithromycin](/search?q=clarithromycin) 500 mg twice daily.
Efficacy: 70–85% (depends on regional clarithromycin resistance). Not recommended as first-line in regions with >15% clarithromycin resistance.
PPI twice daily + [bismuth subsalicylate](/search?q=bismuth%20subsalicylate) (or bismuth subcitrate) 120 mg four times daily + [metronidazole](/search?q=metronidazole) 500 mg three times daily + tetracycline 500 mg four times daily. Efficacy: 85–90%. Preferred with penicillin allergy or high clarithromycin resistance.
If the first regimen failed — replace clarithromycin with [metronidazole](/search?q=metronidazole) (or vice versa) or switch to bismuth quadruple therapy. Ideally — culture with sensitivity testing.
4 weeks after therapy completion — repeat H. pylori test (13C-breath test or stool antigen). Serology is not suitable for confirmation, as antibodies persist for months.
PPIs — the cornerstone of healing. Duodenal ulcer: [omeprazole](/search?q=omeprazole) 20 mg/day (or equivalent) for 4–8 weeks. Gastric ulcer: 8–12 weeks (heals more slowly). PPI mechanism: irreversibly block the proton pump of parietal cells → reduce HCl secretion by 90–98%.
[Sucralfate](/search?q=sucralfate) 1 g four times daily (1 hour before meals) — forms a protective film over the ulcer surface. Used as adjunct or with PPI intolerance.
[Misoprostol](/search?q=misoprostol) 200 mcg four times daily — synthetic prostaglandin E1 analog. Used to prevent NSAID-associated ulcers in high-risk patients. Side effect: diarrhea. Contraindicated in pregnancy (causes uterine contractions).
If long-term NSAIDs are necessary: add a PPI for the entire NSAID course; prefer a selective COX-2 inhibitor (celecoxib) — lower GI risk; eradicate H. pylori before starting long-term NSAID therapy; avoid combining NSAIDs + anticoagulants + corticosteroids.
A strict "gastritis diet" is not scientifically mandatory. Practical recommendations: exclude foods that individually cause symptoms (often spicy, acidic, fried, coffee on empty stomach); eat small frequent meals (5–6 times daily); avoid eating 2–3 hours before bed (if reflux present); quit smoking (slows ulcer healing); limit alcohol (especially spirits, on an empty stomach).
Bleeding — the most common complication (15–20% of ulcers). Presents with hematemesis, melena, hypotension. Treatment: emergency EGD with hemostasis + IV PPI. Perforation — wall penetration → acute abdomen, peritonitis. Emergency surgery. Pyloric stenosis — cicatricial narrowing of the gastric outlet → vomiting of undigested food, weight loss. Endoscopic balloon dilation or surgery. Penetration — ulcer erodes into an adjacent organ (pancreas) → persistent pain unresponsive to antisecretory therapy.
Call emergency services immediately for: vomiting blood or "coffee grounds"; black stool (melena); sudden sharp "dagger-like" abdominal pain with muscle guarding; fainting or acute hypotension; intractable vomiting with inability to drink.
With successful H. pylori eradication, ulcer recurrence occurs in less than 5% of cases (vs. 60–80% without eradication). Modern PPIs achieve >90% ulcer healing within 8 weeks. The key to success is completing the full antibiotic course (don't stop when feeling better!) and confirming eradication.
*This article is for informational purposes only and does not replace medical advice. Consult a gastroenterologist before starting or changing treatment.*
This article is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before making decisions about medications.
Dr. Anna Kowalska is a clinical pharmacist with over 12 years of experience in hospital and community pharmacy settings. She specializes in medication therapy management, drug interactions, and patient safety. Her work focuses on making complex pharmaceutical information accessible to the public.
All articles→